East of England Dementia Trials Network | Powered by the UK Dementia Trials Network and Alzheimer’s Society
We connect NHS clinical care, university research, and specialist facilities into a single accessible front door. Whether you want to place a multi-site commercial study or find a trial for yourself or a family member, we provide one coordinated route into the region.
Core operating model
One region.
One network.
One way in.
Counties connected
Bedfordshire, Cambridgeshire, Essex, Hertfordshire, Norfolk and Suffolk
Enquiry acknowledgement
Initial response target within business hours
Coordinated regional route
A single point for regional feasibility
Clinical lifecycle
Early-phase and experimental medicine capability
Why a regional consortium
Traditionally, setting up a dementia trial meant contacting individual hospital trusts, negotiating separate agreements, and navigating varied clinical pathways. We operate as a unified delivery environment—matching each protocol to the right patient cohorts, clinical investigators, and advanced infrastructure from day one.
Accelerated start-up through aligned NHS and academic partners.
Regional feasibility brings populations, capacity, facilities and specialist teams into one assessment.
Combined regional capability
Deep clinical specialism, advanced diagnostics, and dedicated delivery teams across all stages of dementia research.
01
Memory clinics, early-onset cohorts, rare dementias, and diverse urban and rural reach.
Infrastructure: Established NHS memory-service pathways · Early-onset and genetically defined cohorts · Urban, rural and coastal communities · PPIE-supported recruitment planning
02
Phase I, Ib and II capability, including first-in-human studies.
Infrastructure: Early-phase protocol delivery · Intensive pharmacokinetic schedules · First-in-human governance · Specialist medical cover
03
Intrathecal delivery, antisense oligonucleotides, gene-silencing and novel mAbs.
Infrastructure: Intrathecal administration pathways · ASO and gene-silencing expertise · Novel monoclonal antibodies · Complex safety monitoring
04
3T and 7T MRI, amyloid and tau PET, and total-body PET at Wolfson Brain Imaging Centre.
Infrastructure: 3T and ultra-high-field 7T MRI · Amyloid and tau PET · Total-body PET capability · Quantitative image analysis
05
CSF, plasma p-tau217, NfL and high-throughput assays.
Infrastructure: CSF collection and processing · Plasma p-tau217 and NfL · High-throughput assay platforms · Sample handling and biobanking
06
Dedicated CRFs and experienced dementia research nursing teams.
Infrastructure: Purpose-designed participant facilities · Specialist research nursing · Complex visit delivery · Extended observation capacity
07
Neuro CTU expertise spanning design, statistics, operations and regulation.
Infrastructure: Protocol and statistical design · Trial management and data systems · Regulatory and quality support · Neuroscience methodology
08
Connected investigators and participant partners shaping relevant, accessible studies.
Infrastructure: Regional principal investigator network · Specialist dementia expertise · Public and patient involvement · Community-informed study design
Leadership and clinical delivery
Named clinical leadership, participant nursing support, and regional trial coordination across the East of England.
Regional scientific leadership, feasibility governance and UKDTN coordination.
Cambridge University Hospitals NHS FT / University of Cambridge
Clinical support for participants and families from enquiry through clinic visits.
Alzheimer’s Society & Regional Clinical Research Facility
Site-level trial delivery, patient identification and protocol leadership.
Regional NHS acute and mental health trusts
Study onboarding, governance and multi-site logistics.
Central Consortium Coordination Office
For sponsor feasibility, investigator collaboration or regional trust membership queries.
Contact Central CoordinationConsortium partners
A partnership anchored in Cambridge and delivered with regional NHS providers.
Trial portfolio
Clear information on study phase, indication and participating location.
Phase I
Early symptomatic
Cambridge University Hospitals
Check eligibility & enquirePhase I
Early symptomatic
Cambridge University Hospitals
Check eligibility & enquirePhase I
Early symptomatic
Cambridge University Hospitals
Check eligibility & enquireStudy eligibility is confirmed through clinical triage. Taking part is always voluntary, and you can withdraw at any time.
Get involved
Pathway A
Research trials test new diagnostic tools, therapies and care approaches. Taking part is optional and does not affect your standard NHS care.
What you’ll need: Your approximate location and diagnosis stage, if known
Check suitable research opportunitiesPathway B
A single point of contact to evaluate feasibility, identify participants and access specialist early-phase infrastructure.
What you’ll need: Study phase, modality, target timeline and criteria
Submit study for feasibility assessmentRegional coverage
High-intensity procedures and advanced imaging are concentrated around Cambridge, while recruitment and routine visits can take place through regional NHS services.
Cambridge University Hospitals NHS FT · Cambridgeshire & Peterborough NHS FT
Norfolk & Norwich University Hospitals NHS FT · Norfolk & Suffolk NHS FT
West Suffolk NHS FT · East Suffolk & North Essex NHS FT
Mid and South Essex NHS FT · Essex Partnership University NHS FT
Hertfordshire Partnership University NHS FT · East and North Hertfordshire NHS Trust
Bedfordshire Hospitals NHS FT
Regional NHS Trust or memory clinic?
Ask about joining the delivery network and opening trial access for patients.
Standards and safety
HRA and MHRA approvals apply to regulated studies.
National trial quality standards guide delivery.
Monitoring and independent oversight protect participants.
“Being part of a trial gave my family hope and direct access to clinicians who specialise in this condition. The research nurses made every clinic visit feel safe and supported.”
Start enquiry
Choose the route that fits your enquiry. The consortium aims to acknowledge enquiries within 48 business hours.
Participant or family member
Sponsor or CRO
Clinician or investigator
Regional NHS trust